Opendata, web and dolomites

DIALYBRID

Revolutionising the world of hemodialysis with a novel, hybrid, silk fibroin/polyurethane vascular access

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 DIALYBRID project word cloud

Explore the words cloud of the DIALYBRID project. It provides you a very rough idea of what is the project "DIALYBRID" about.

ftes    competitiveness    integration    functioning    skilled    bottleneck    people    accesses    master    meet    complications    soundness    innovative    fact    turnover    health    patients    renal    scenario    create    trademarked    polyurethane    quality    validation    ip    million    worldwide    54m    de    hybrid    diabetes    limitations    risk    placement    market    reg    infective    enter    longer    sustaining    frequency    semidegradable    remodeling    revolutionize    frequent    granting    interventions    commercialization    verify    portfolio    nanostructured    suffer    business    hypertension    2025    electrospinning    hemodialysis    msca    live    global    arteriovenous    consequence    28    sag    urgent    productivity    jobs    commercial    view    viability    proposes    silk    opportunity    fibroin    saving    38    certification    sme    vascular    increment    re    members    2030    costly    industrialization    graft    human    cannulation    reducing    reached    auspices    trl    delivering    society    materials    life    diversify    silkothane       clinical    therapy    blend    patency    venture    action    plan    manufactured    36    bel    technological    alternatives    470   

Project "DIALYBRID" data sheet

The following table provides information about the project.

Coordinator
BIOENGINEERING LABORATORIES 

Organization address
address: VIA VIVALDI 32/A
city: CANTU'
postcode: 22063
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.bioengineeringlab.com/eng/sme-instrument-phase-1-dialybrid-december-1-2018/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOENGINEERING LABORATORIES IT (CANTU') coordinator 50˙000.00

Map

 Project objective

Vascular access is the bottleneck to long-term hemodialysis for about 2.2 million people worldwide who need this life-saving/life-sustaining therapy in case of renal failure, e.g. as a consequence of diabetes and/or hypertension. The current alternatives of vascular access suffer in fact from several limitations, e.g. the need for frequent and costly re-interventions, reduced patency, infective complications. To meet this urgent, global, clinical need, BEL proposes SAG (Silkothane® Arteriovenous Graft), an innovative, hybrid, semidegradable, nanostructured vascular access, manufactured by electrospinning using Silkothane®, a silk fibroin/polyurethane blend developed and trademarked by BEL under the auspices of a MSCA action. Enabling early cannulation and easy placement, as well as remodeling, patency, and integration on the long term, SAG will revolutionize the scenario of hemodialysis vascular accesses worldwide by: reducing the frequency of complications and re-interventions (thus health costs); granting broader access to hemodialysis; improving the patients’ quality of life, enabling them to live longer as functioning members of the society. SAG has reached TRL 6. Phase 1 would allow BEL to verify the soundness of SAG’s venture (with a Business Plan and an IP Management Plan), and to de-risk the technological viability of the industrialization (delivering Essential Requirements, Risk Analysis, Validation Master Plan, Industrialization Plan), in view of future clinical studies, certification and commercialization. SAG represents for BEL an important opportunity to diversify its product portfolio, enter the market of Advanced Materials, experience growth in productivity and competitiveness and create new jobs. As the commercial potential of SAG is estimated to be around 28 million € in 2025 and 54M€ in 2030, in 2025 the SME would experience an increment in turnover of about 470%, and a 36% increase (from 28 FTEs to 38 FTEs) in highly skilled human resources.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DIALYBRID" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DIALYBRID" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More